MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this
Price Non-Member $30.00

Preview this :
Zoom in

, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch104-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch104-2.gif
There is no abstract provided for this chapter. We are in the process of generating a full text preview. Please bookmark and return later.
Citation: Ginocchio C, Gravitt P, Smith J. .
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Photograph of KA. LSILs on Pap smears are characterized by high nucleus/cytoplasm ratios and the presence of KA, which is defined as the presence of nuclear atypia as well as a clearly defined perinuclear halo in cervical epithelial cells. Photograph courtesy of Patricia Wasserman, Division of Cytopathology, Department of Pathology and Laboratory Medicine, North Shore-LIJ Health System, Lake Success, NY. doi:10.1128/9781555817381.ch104.f1

Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

American Society for Colposcopy and Cervical Pathology 2006 consensus conference recommendations for HPV type 16 or 18 detection (from http://www.asccp.org/pdfs/consensus/clinical_update_20090408.pdf). doi:10.1128/9781555817381.ch104.f2

Permissions and Reprints Request Permissions
Download as Powerpoint


1. Bernard HU,, Burk RD,, Chen Z,, van Doorslaer K,, Hausen HZ,, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:7079.
2. Bernard HU. 2002. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir Ther 7:219237.
3. Badal V,, Chuang LS,, Tan EH,, Badal S,, Villa LL,, Wheeler CM,, Li BF,, Bernard HU. 2003. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 77:62276234.
4. Badal S,, Badal V,, Calleja-Macias IE,, Kalantari M,, Chuang LS,, Li BF,, Bernard HU. 2004. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 324:483492.
5. Vinokurova S,, von Knebel Doeberitz M. 2011. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One 6(9):e24451. 10.1371/journal.pone .0024451.
6. Huibregtse JM,, Scheffner M,, Howley PM. 1993. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13:49184927.
7. Scheffner M,, Werness BA,, Huibregts JM,, Levine AJ,, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:11291136.
8. Dyson N,, Howley PM,, Munger K,, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934937.
9. Munger K,, Werness BA,, Dyson N,, Phelps WC,, Harlow E,, Howley PM. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:40994105.
10. Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110:525541.
11. Vinokurova S,, Wentzensen N,, Kraus I,, Klaes R,, Driesch C,, Melsheimer P,, Kisseljov F,, Durst M,, Schneider A,, von Knebel Doeberitz M. 2008. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68:307313.
12. Pett M,, Coleman N. 2007. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 212:356367.
13. Pett MR,, Alazawi WO,, Roberts I,, Dowen S,, Smith DI,, Stanley MA,, Coleman N. 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 64:13591368.
14. Feltkamp M,, de Koning MN,, Bavinck JN,, Ter Schegget T. 2008. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 43:353360.
15. Hernandez BY,, Wilkens LR,, Zhu X,, Thompson P,, McDuffie K,, Shvetsov YB,, Kamemoto LE,, Killeen J,, Ning L,, Goodman MT. 2008. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 14:888894.
16. Burchell AN,, Coutlee F,, Tellier PP,, Hanley J,, Franco EL. 2011. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis 204:17231729.
17. Partridge JM,, Hughes JP,, Feng Q,, Winer RL,, Weaver BA,, Xi LF,, Stern ME,, Lee SK,, O’Reilly SF,, Hawes SE,, Kiviat NB,, Koutsky LA. 2007. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 196:11281136.
18. Hessol NA,, Holly EA,, Efird JT,, Minkoff H,, Weber KM,, Darragh TM,, Burk RD,, Strickler HD,, Greenblatt RM,, Palefsky JM. 2013. Concomitant anal and cervical human papillomavirus infections and intraepithelial neoplasia in HIV-infected and uninfected women. AIDS 27:17431751.
19. Winer RL,, Hughes JP,, Feng Q,, O’Reilly S,, Kiviat NB,, Holmes KK,, Koutsky LA. 2006. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354:26452654.
20. Miksis S. 2008. A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of human papillomavirus infections. J Obstet Gynecol Neonatal Nurs 37:329337.
21. Pierce Campbell CM,, Lin HY,, Fulp W,, Papenfuss MR,, Salmeron JJ,, Quiterio MM,, Lazcano-Ponce E,, Villa LL,, Giuliano AR. 2013. Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in study. J J Infect Dis 208:373384.
22. Patel SJ,, Mugo NR,, Cohen CR,, Ting J,, Nguti R,, Kwatampora J,, Waweru W,, Patnaik P,, Donders GG,, Kimani J,, Kenney DL,, Kiviat NB,, Smith JS. 2013. Multiple human papillomavirus infections and HIV seropositivity as risk factors for abnormal cervical cytology among female sex workers in Nairobi. Int J STD AIDS 24:221225.
23. Gravitt PE. 2011. The known unknowns of HPV natural history. J Clin Invest 121:45934599.
24. Burchell AN,, Richardson H,, Mahmud SM,, Trottier H,, Tellier PP,, Hanley J,, Coutlee F,, Franco EL. 2006. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 163:534543.
25. Centers for Disease Control and Prevention. 2012. Human Papillomavirus Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 12th ed, 2nd printing. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html.
26. Winer RL,, Lee SK,, Hughes JP,, Adam DE,, Kiviat NB,, Koutsky LA. 2003. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157:218226.
27. Winer RL,, Feng Q,, Hughes JP,, O’Reilly S,, Kiviat NB,, Koutsky LA. 2008. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197:279282.
28. Rositch AF,, Koshiol J,, Hudgens MG,, Razzaghi H,, Backes DM,, Pimenta JM,, Franco EL,, Poole C,, Smith JS. 2013. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 133:12711285.
29. Zhang P,, Nouri M,, Brandsma JL,, Iftner T,, Steinberg BM. 1999. Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology 263:388394.
30. Kjaer SK,, Frederiksen K,, Munk C,, Iftner T. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102:14781488.
31. Marks MA,, Castle PE,, Schiffman M,, Gravitt PE. 2012. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol 50:300306.
32. Carter JJ,, Koutsky LA,, Wipf GC,, Christensen ND,, Lee SK,, Kuypers J,, Kiviat N,, Galloway DA. 1996. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927936.
33. Edelstein ZR,, Carter JJ,, Garg R,, Winer RL,, Feng Q,, Galloway DA,, Koutsky LA. 2011. Serum antibody response following genital α9 human papillomavirus infection in young men. J Infect Dis 204:209216.
34. Wentzensen N,, Rodriguez AC,, Viscidi R,, Herrero R,, Hildesheim A,, Ghosh A,, Morales J,, Wacholder S,, Guillen D,, Alfaro M,, Safaeian M,, Burk RD,, Schiffman M. 2011. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 204:94102.
35. Wilson L,, Pawlita M,, Castle PE,, Waterboer T,, Sahasrabuddhe V,, Gravitt PE,, Schiffman M,, Wentzensen N. 25 February 2014. Seroprevalence of 8 oncogenic human papillomaviruses and acquired immunity against re-infection. J Infect Dis 10.1093/infdis/jiu104.
36. Lu B,, Viscidi RP,, Wu Y,, Lee JH,, Nyitray AG,, Villa LL,, Lazcano-Ponce E,, da Silva RJ,, Baggio ML,, Quiterio M,, Salmeron J,, Smith DC,, Abrahamsen ME,, Papenfuss MR,, Stockwell HG,, Giuliano AR. 2012. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 72:676685.
37. Moscicki AB,, Ma Y,, Farhat S,, Jay J,, Hanson E,, Benningfield S,, Jonte J,, Godwin-Medina C,, Wilson R,, Shiboski S. 2014. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis 58:804811.
38. Videla S,, Darwich L,, Canadas MP,, Coll J,, Pinol M,, Garcia-Cuyas F,, Molina-Lopez RA,, Cobarsi P,, Clotet B,, Sirera G, HIV-HPV Study Group. 2013. Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 40:310.
39. Giuliano A,, Lu B,, Nielson CM,, Flores R,, Papenfuss MR,, Lee JH,, Abrahamsen M,, Harris RB. 2008. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198:827835.
40. Giuliano AR,, Lee JH,, Fulp W,, Villa LL,, Lazcano E,, Papenfuss MR,, Abrahamsen M,, Salmeron J,, Anic GM,, Rollison DE,, Smith D. 2011. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377:932940.
41. Mbulawa ZZ,, Marais DJ,, Johnson LF,, Coetzee D,, Williamson AL. 2012. Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women. J Infect Dis 206:1527.
42. Lu B,, Wu Y,, Nielson CM,, Flores R,, Abrahamsen M,, Papenfuss M,, Harris RB,, Giuliano AR. 2009. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 199:362371.
43. Tobian AA,, Serwadda D,, Quinn TC,, Kigozi G,, Gravitt PE,, Laeyendecker O,, Charvat B,, Ssempijja V,, Riedesel M,, Oliver AE,, Nowak RG,, Moulton LH,, Chen MZ,, Reynolds SJ,, Wawer MJ,, Gray RH. 2009. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 360:12981309.
44. Auvert B,, Sobngwi-Tambekou J,, Cutler E,, Nieuwoudt M,, Lissouba P,, Puren A,, Taljaard D. 2009. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 199:1419.
45. Gray RH,, Serwadda D,, Kong X,, Makumbi F,, Kigozi G,, Gravitt PE,, Watya S,, Nalugoda F,, Ssempijja V,, Tobian AA,, Kiwanuka N,, Moulton LH,, Sewankambo NK,, Reynolds SJ,, Quinn TC,, Iga B,, Laeyendecker O,, Oliver AE,, Wawer MJ. 2010. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 201:14551462.
46. Machalek DA,, Grulich AE,, Jin F,, Templeton DJ,, Poynten IM. 2012. The epidemiology and natural history of anal human papillomavirus infection in men who have sex with men. Sex Health 9:527537.
47. Torres M,, Gonzalez C,, del Romero J,, Viciana P,, Ocampo A,, Rodriguez-Fortunez P,, Masiá M,, Blanco JR,, Portilla J,, Rodríguez C,, Hernández-Novoa B,, del Amo J,, Ortiz M, CoRIS-HPV Study Group. 2013. Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort. J Clin Microbiol 51:35123520.
48. Wiley DJ,, Li X,, Hsu H,, Seaberg EC,, Cranston RD,, Young S,, D’Souza G,, Martínez-Maza O,, DeAzambuja K,, Chua K,, Hussain SK,, Detels R. 2013. Factors affecting the prevalence of strongly and weakly carcinogenic and lower-risk human papillomaviruses in anal specimens in a cohort of men who have sex with men (MSM). PLoS One 8:e79492. 10.1371/journal.pone.0079492.
49. Gillison ML,, Koch WM,, Capone RB,, Spafford M,, Westra WH,, Wu L,, Zahurak ML,, Daniel RW,, Viglione M,, Symer DE,, Shah KV,, Sidransk D. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709720.
50. Gillison ML,, Broutian T,, Pickard RK,, Tong ZY,, Xiao W,, Kahle L,, Graubard BI,, Chaturvedi AK. 2012. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307:693703.
51. Kreimer AR,, Pierce Campbell CM,, Lin HY,, Fulp W,, Papenfuss MR,, Abrahamsen M,, Hildesheim A,, Villa LL,, Salmerón JJ,, Lazcano-Ponce E,, Giuliano AR. 2013. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 382:877887.
52. Beachler DC,, D’Souza G,, Sugar EA,, Xiao W,, Gillison ML. 2013. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 208:330339.
53. Melnikow J,, McGahan C,, Sawaya GF,, Ehlen T,, Coldman A. 2009. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 101:721728.
54. Chan BK,, Melnikow J,, Slee CA,, Arellanes R,, Sawaya GF. 2009. Post treatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 200:422.e1–422.e9.
55. de Pokomandy A,, Rouleau D,, Ghattas G,, Vezina S,, Cote P,, Macleod J,, Allaire G,, Franco EL,, Coutlee F. 2009. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 199:965973.
56. O’Rorke MA,, Ellison MV,, Murray LJ,, Moran M,, James J,, Anderson LA. 2012. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 48:11911201.
57. Giuliano AR,, Palefsky JM,, Goldstone S,, Moreira ED,, Penny ME,, Aranda C,, Vardas E,, Moi H,, Jessen H,, Hillman R,, Chang YH,, Ferris D,, Rouleau D,, Bryan J,, Marshall JB,, Vuocolo S,, Barr E,, Radley D,, Haupt RM,, Guris D. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401411.
58. The Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:19151927.
59. Garland SM,, Hernandez-Avila M,, Wheeler CM,, Perez G,, Harper DM,, Leodolter S,, Tang GW,, Ferris DG,, Steben M,, Bryan J,, Taddeo FJ,, Railkar R,, Esser MT,, Sings HL,, Nelson M,, Boslego J,, Sattler C,, Barr E,, Koutsky LA. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:19281943.
60. Paavonen J,, Naud P,, Salmeron J,, Wheeler CM,, Chow SN,, Apter D,, Kitchener H,, Castellsague X,, Teixeira JC,, Skinner SR,, Hedrick J,, Jaisamrarn U,, Limson G,, Garland S,, Szarewski A,, Romanowski B,, Aoki FA,, Schwarz TF,, Poppe WA,, Bosch FX,, Jenkins D,, Hardt K,, Zahaf T,, Descamps D,, Struyf F,, Lehtinen M,, Dubin G,, Greenacre M. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301314.
61. Moyer VA. 2012. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156:880891, W312.
62. Saslow D,, Solomon D,, Lawson HW,, Killackey M,, Kulasingam SL,, Cain J,, Garcia FA,, Moriarty AT,, Waxman AG,, Wilbur DC,, Wentzensen N,, Downs LSJr,, Spitzer M,, Moscicki AB,, Franco EL,, Stoler MH,, Schiffman M,, Castle PE,, Myers ER, ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147172.
63. Massad LS,, Einstein MH,, Huh WK,, Katki HA,, Kinney WK,, Schiffman M,, Solomon D,, Wentzensen N,, Lawson HW, 2012 ASCCP Consensus Guidelines Conference. 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract 17(5 Suppl 1):S1S27.
64. Qiagen. 2005. Hybrid Capture 2 High-Risk HPV DNA Test. US package insert L2248. Qiagen, Gaithersburg, MD.
65. Hologic. 2012. Cervista HPV HR. US package insert P/N 15–3100, rev 102. Hologic, Madison, WI.
66. Roche. April 2011. cobas 4800 HPV Test. US package insert. Roche Molecular Systems, Inc, Pleasanton, CA.
67. Gen-Probe/Hologic. 2013. Aptima HPV Assay. US package insert 503789, rev A. Gen-Probe/Hologic, San Diego, CA.
68. Dixon EP,, King LM,, Adams MD,, Grønn P,, Murphy PG,, Brown CA,, Brough GH,, Skomedal H,, Malinowski DP,, Fischer TJ. 2008. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTec HPV-Proofer assay. J Virol Methods 154:220222.
69. Dixon EP,, Lenz KL,, Doobay H,, Brown CA,, Malinowski DP,, Fischer TJ. 2010. Recovery of DNA from BD SurePath cytology specimens and compatibility with the Roche AMPLICOR human papillomavirus (HPV) test. Clin Virol 48:3135.
70. McMenamin M,, McKenna M. 2013. Effect of glacial acetic acid treatment of cervical ThinPrep specimens on HPV DNA detection with the cobas 4800 HPV test. Cytopathology 24:321326.
71. Dzuba IG,, Diaz EY,, Allen B,, Leonard YF,, Lazcano Ponce EC,, Shah KV,, Bishai D,, Lorincz A,, Ferris D,, Turnbull B,, Hernandez Avila M,, Salmeron J. 2002. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 11:265275.
72. Stewart DE,, Gagliardi A,, Johnston M,, Howlett R,, Barata P,, Lewis N,, Oliver T,, Mai V. 2007. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynaecol Can 29:817828.
73. Arbyn M,, Verdoodt F,, Snijders PJ,, Verhoef VM,, Suonio E,, Dillner,, Anttila A. 2014. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15:172183.
74. Tisci S,, Shen YH,, Fife D,, Huang J,, Goycoolea J,, Ma CP,, Qiao YL. 2003. Patient acceptance of self-sampling for human papillomavirus in rural china. J Low Genit Tract Dis 7:107116.
75. Snijders PJ,, Verhoef VM,, Arbyn M,, Ogilvie G,, Minozzi S,, Banzi R,, Meijer CJ. 2013. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132:22232236.
76. Sahasrabuddhe V,, Gravitt P,, Dunn ST,, Robbins D,, Brown D,, Allen R,, Eby Y,, Smith K,, Zuna R,, Zhang R,, Gold M,, Schiffman M,, Walker J,, Castle P,, Wentzensen N. 2014. Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. J Clin Virol 60:414417.
77. Gravitt PE,, Belinson JL,, Salmeron J,, Shah KV. 2011. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer 129:517527.
78. Solomon D,, Davey D,, Kurman R,, Moriarty A,, O’Connor D,, Prey M,, Raab S,, Sherman M,, Wilbur D,, Wright TJr,, Young N. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 21142119.
79. Siebers AG,, Klinkhamer PJ,, Arbyn M,, Raifu AO,, Massuger LF,, Bulten J. 2008. Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial. Obstet Gynecol 112:13271334.
80. Siebers AG,, Klinkhamer PJ,, Grefte JM,, Massuger LF,, Vedder JE,, Beijers-Broos A,, Bulten J,, Arbyn M. 2009. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 302:17571764.
81. Wentzensen N,, Follansbee S,, Borgonovo S,, Tokugawa D,, Schwartz L,, Lorey TS,, Sahasrabuddhe VV,, Lamere B,, Gage JC,, Fetterman B,, Darragh TM,, Castle PE. 2012. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. AIDS 26:21852192.
82. Gustinucci D,, Passamonti B,, Cesarini E,, Butera D,, Palmieri EA,, Bulletti S,, Carlani A,, Staiano M,, D’Amico MR,, D’Angelo V,, Di Dato E,, Martinelli N,, Malaspina M,, Spita N,, Tintori B,, Fulciniti F. 2012. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Acta Cytol 56:506514.
83. Roelens J,, Reuschenbach M,, von Knebel Doeberitz M,, Wentzensen N,, Bergeron C,, Arbyn M. 2012. p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol 120:294307.
84. Mesher D,, Szarewski A,, Cadman L,, Austin J,, Ashdown-Barr L,, Ho L,, Terry G,, Young M,, Stoler M,, Bergeron C,, McCarthy J,, Wright C,, Liddle S,, Soutter WP,, Lyons D,, Cuzick J. 2013. Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. Eur J Cancer 49:21792186.
85. Waldstrøm M,, Christensen RK,, Ørnskov D. 2013. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol 121:136145.
86. Darragh TM,, Colgan TJ,, Cox JT,, Heller D,, Henry MR,, Luff RD,, McCalmont T,, Nayar R,, Palefsky JM,, Stoler MH,, Wilkinson EJ,, Zaion RJ,, Wilbur DC, Members of the Last Project Work Groups. 2012. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 16:205242.
87. Poljak M,, Kocjan BJ. 2010. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 8:11391162.
88. Burger EA,, Kornor H,, Klemp M,, Lauvrak V,, Kristiansen IS. 2011. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 120:430438.
89. Poljak M,, Cuzik J,, Kocjan BJ,, Iftner T,, Dillner J,, Arbyn M. 2012. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 30S:F110F106.
90. Meijer CJ,, Berkhof J,, Castle PE,, Hesselink AT,, Franco EL,, Ronco G,, Arbyn M,, Bosch FX,, Cuzick J,, Dillner J,, Heideman DA,, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516520.
91. Meijer CJ,, Berkhof H,, Heideman DAM,, Hesselink AT,, Snijders PJF. 2009. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 46:S1S4.
92. Schutzbank TE,, Ginocchio CC. 2012. Assessment of clinical and analytical performance characteristics of an HPV genotyping test. Diagn Cytopathol 40:367373.
93. Gravitt PE,, Peyton CL,, Alessi TQ,, Wheeler CM,, Coutlee F,, Hildesheim A,, Schiffman MH,, Scott DR,, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38:357361.
94. Cuzick J,, Arbyn M,, Sankaranarayanan R,, Tsu V,, Ronco G,, Mayrand MH,, Dillner J,, Meijer CJLM. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26:K29K41.
95. Castle PE,, Schiffman M,, Burk RD,, Wacholder S,, Hildesheim A,, Herrero R,, Bratti MC,, Sherman ME,, Lorincz A. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 11:13941399.
96. Castle PE,, Solomon D,, Wheeler CM,, Gravitt PE,, Wacholder S,, Schiffman M. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol 46:25952604.
97. Gravitt PE,, Schiffman M,, Solomon D,, Wheeler CM,, Castle PE. 2008. A comparison of Linear Array and Hybrid Capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 17:12481254.
98. Einstein MH,, Martens MG,, Garcia FA,, Ferris DG,, Mitchell AL,, Day SP,, Olson MC. 2010. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 118:116122.
99. Belinson JL,, Wu R,, Belinson SE,, Qu X,, Yang B,, Du H,, Wu R,, Wang C,, Zhang L,, Zhou Y,, Liu Y,, Pretorius RG. 2011. A population-based clinical trial comparing endocervical high-risk HPV testing using Hybrid Capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol 135:790795.
100. Youens KE,, Hosler GA,, Washington PJ,, Jenevein EP,, Murphy KM. 2011. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn 13:160166.
101. Rao A,, Young S,, Erlich H,, Boyle S,, Krevolin M,, Sun R,, Apple R,, Behrens C. 2013. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol 51:14781484.
102. Castle PE,, Stoler MH,, Wright TCJr,, Sharma A,, Wright TL,, Behrens CM. 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12:880890.
103. Stoler MH,, Wright TCJr,, Sharma A,, Zhang G,, Apple R,, Wright TL,, Behrens CM, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. 2012. The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol 137:295303.
104. Gage JC,, Sadorra M,, Lamere BJ,, Kail R,, Aldrich C,, Kinney W,, Fetterman B,, Lorey T,, Schiffman M,, Castle PE, PaP Cohort Study Group. 2012. Comparison of the cobas human papillomavirus (HPV) test with the Hybrid Capture 2 and Linear Array HPV DNA tests. J Clin Microbiol 50:6165.
105. Lapierre SG,, Sauthier P,, Mayrand MH,, Dufresne S,, Petignat P,, Provencher D,, Drouin P,, Gauthier P,, Dupuis MJ,, Michon B,, Ouellet S,, Hadjeres R,, Ferenczy A,, Franco EL,, Coutlée F. 2012. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 50:12401244.
106. Stoler MH,, Wright TCJr,, Cuzick J,, Dockter J,, Reid JL,, Getman D,, Giachetti C. 2013. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 208:144.e1–144.e8.
107. Wu R,, Belinson SE,, Du H,, Na W,, Qu X,, Wu R,, Liu Y,, Wang C,, Zhou Y,, Zhang L,, Belinson JL. 2010. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 20:14111414.
108. Monsonego J,, Hudgens MG,, Zerat L,, Zerat JC,, Syrjänen K,, Halfon P,, Ruiz F,, Smith JS. 2011. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 129:691701.
109. Ratnam S,, Coutlee F,, Fontaine D,, Bentley J,, Escott N,, Ghatage P,, Gadag V,, Holloway G,, Bartellas E,, Kum N,, Giede C,, Lear A. 2011. APTIMA HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 49:557564.
110. Monsonego J,, Hudgens MG,, Zerat L,, Zerat JC,, Syrjänen K,, Smith JS. 2012. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecol Oncol 125:175180.
111. Arbyn M,, Roelens J,, Cuschieri K,, Cuzick J,, Szarewski A,, Ratnam S,, Reuschenbach M,, Belinson S,, Belinson JL,, Monsonego J. 2013. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 132:101108.
112. Szarewski A,, Ambroisine L,, Cadman L,, Austin J,, Ho L,, Terry G,, Liddle S,, Dina R,, McCarthy J,, Buckley H,, Bergeron C,, Soutter P,, Lyons D,, Cuzick J. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17:30333042.
113. Szarewski A,, Mesher D,, Cadman L,, Austin J,, Ashdown-Barr L,, Ho L,, Terry G,, Liddle S,, Young M,, Stoler M,, McCarthy J,, Wright C,, Bergeron C,, Soutter WP,, Lyons D,, Cuzick J. 2012. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 50:18671873.
114. Cuzick J,, Cadman L,, Mesher D,, Austin J,, Ashdowner-Barr L,, Ho L,, Terry G,, Liddle S,, Wright C,, Lyons D,, Szarewski A. 2013. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 108:908913.
115. American Society for Colposcopy and Cervical Pathology. 2006. American Society for Colposcopy and Cervical Pathology 2006 consensus conference recommendations for HPV type 16 or 18 detection. American Society for Colposcopy and Cervical Pathology, Frederick, MD. http://www.asccp.org/Guidelines/Screening
116. Khan MJ,, Castle PE,, Lorincz AT,, Wacholder S,, Sherman M,, Scott DR,, Rush BB,, Glass AG,, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:10721079.
117. Hologic. 2010. Cervista HPV 16/18. US package insert P/N 15–3101, rev 100. Hologic, Madison, WI.
118. Einstein MH,, Garcia FA,, Mitchell AL,, Day SP. 2011. Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology. Cancer Epidemiol Biomarkers Prev 20:11851189.
119. Gen-Probe/Hologic. 2013. Aptima HPV 16, 18/45 Genotyping Assay. US package insert AW-10840, rev 001. Gen-Probe/Hologic, San Diego, CA.
120. Martínez SB,, Palomares JC,, Artura A,, Parra M,, Cabezas JL,, Romo JM,, Martín-Mazuelos E. 2012. Comparison of the cobas 4800 human papillomavirus test against a combination of the Amplicor human papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J Virol Methods 180:710.
121. Basu P,, Chandna P,, Bamezai RN,, Siddiqi M,, Saranath D,, Lear A,, Ratnam S. 2011. MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer. J Clin Microbiol 49:35373544.
122. Peng J,, Gao L,, Guo J,, Wang T,, Wang L,, Yao Q,, Zhu H,, Jin Q. 2013. Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes. J Clin Microbiol 51:402408.
123. Clarke MA,, Wentzensen N,, Mirabello L,, Ghosh A,, Wacholder S,, Harari A,, Lorincz A,, Schiffman M,, Burk RD. 2012. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 21:21252137.
124. Lorincz AT. 2014. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn 14:293305.
125. Nye MD,, Hoyo C,, Huang Z,, Vidal AC,, Wang F,, Overcash F,, Murphy SK. 2013. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS One 8:e56325. 10.1371/journal.pone.0056325.
126. Carter JJ,, Koutsky LA,, Hughes JP,, Lee SK,, Kuypers J,, Kiviat N,, Galloway DA. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 19111919.
127. Schiller JT,, Lowy DR. 2009. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 200:166171.
128. Ronco G,, Dillner J,, Elfstrom KM,, Tunesi S,, Snijders PJF,, Arbyn M,, Kitchener H,, Segnan N,, Gilham C,, Giorgi-Rossi P,, Berkhof J,, Peto J,, Meijer CJLM. 2013. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet 383:524532.
129. Lizard G,, Démares-Poulet MJ,, Roignot P,, Gambert P. 2001. In situ hybridization detection of single-copy human papillomavirus on isolated cells, using a catalyzed signal amplification system: GenPoint. Diagn Cytopathol 24:112116.
130. Kong CS,, Balzer BL,, Troxell ML,, Patterson BK,, Longacre TA. 2007. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol 31:3343.
131. Pierry D,, Weiss G,, Lack B,, Chen V,, Fusco J. 2012. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch Pathol Lab Med 136:956960.
132. Carozzi FM,, Burroni E,, Bisanzi S,, Puliti D,, Confortini M,, Giorgi Rossi P,, Sani C,, Scalisi A,, Chini F. 2011. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol 49:14461451.
133. Cuzick J,, Ambroisine L,, Cadman L,, Austin J,, Ho L,, Terry G,, Liddle S,, Dina R,, McCarthy J,, Buckley H,, Bergeron C,, Soutter WP,, Lyons D,, Szarewski A. 2010. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 82:11861191.
134. Hesselink AT,, Meijer CJ,, Poljak M,, Berkhof J,, van Kemenade FJ,, van der Salm ML,, Bogaarts M,, Snijders PJ,, Heideman DA. 2013. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol 51:24092410.
135. Huang S,, Tang N,, Mak WB,, Erickson B,, Salituro J,, Li Y,, Krumpe E,, Schneider G,, Yu H,, Robinson J,, Abravaya K. 2009. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 45(Suppl 1): S13S17.
136. Park Y,, Lee E,, Choi J,, Jeong S,, Kim HS. 2012. Comparison of the Abbott RealTime High-Risk human papillomavirus (HPV), Roche cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol 50:23592365.
137. Poljak M,, Ostrbenk A,, Seme K,, Ucakar V,, Hillemanns P,, Bokal EV,, Jancar N,, Klavs I. 2011. Comparison of clinical and analytical performance of the Abbott RealTime High-Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening. J Clin Microbiol 49:17211729.
138. Choi J,, Park Y,, Lee EH,, Kim S,, Kim JH,, Kim HS. 2013. Detection and genotyping of human papillomavirus by five assays according to cytologic results. J Virol Methods 187:7984.
139. Gage JC,, Ajenifuja KO,, Wentzensen N,, Adepiti AC,, Stoler M,, Eder PS,, Bell L,, Shrestha N,, Eklund C,, Reilly M,, Hutchinson M,, Wacholder S,, Castle PE,, Burk RD,, Schiffman M. 2012. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 131:29032909.
140. Min KJ,, So KA,, Lee J,, Hong HR,, Hong JH,, Lee JK,, Kim AR. 2012. Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media. J Gynecol Oncol 23:510.
141. Ki EY,, Kim HE,, Choi YJ,, Park JS,, Kang CS,, Lee A. 2013. Comparison of the cobas 4800 HPV test and the Seeplex HPV4A ACE with the Hybrid Capture 2 test. Int J Med Sci 10:119123.
142. Halfon P,, Benmoura D,, Agostini A,, Khiri H,, Martineau A,, Penaranda G,, Blanc B. 2010. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 47:177181.
143. Cattani P,, Zannoni GF,, Ricci C,, D’Onghia S,, Trivellizzi IN,, Di Franco A,, Vellone VG,, Durante M,, Fadda G,, Scambia G,, Capelli G,, De Vincenzo R. 2009. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 47:38953901.
144. Alaghehbandan R,, Fontaine D,, Bentley J,, Escott N,, Ghatage P,, Lear A,, Coutlee F,, Ratnam S. 2013. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the Hybrid Capture 2 HPV DNA test for triaging ASCUS and LSIL cytology. Diagn Cytopathol 41:767775.
145. Andersson S,, Mints M,, Weiderpass E,, Johansson B. 2013. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening. Curr Pharm Des 19:15081515.
146. Benevolo M,, Vocaturo A,, Caraceni D,, French D,, Rosini S,, Zappacosta R,, Terrenato I,, Ciccocioppo L,, Frega A,, Giorgi Rossi P. 2011. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 49:26432650.
147. Keegan H,, McInerney J,, Pilkington L,, Grønn P,, Silva I,, Karlsen F,, Bolger N,, Logan C,, Furuberg L,, O’Leary J,, Martin C. 2009. Comparison of HPV detection technologies: Hybrid Capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods 155:6166.
148. Rijkaart DC,, Heideman DA,, Coupe VM,, Brink AA,, Verheijen RH,, Skomedal H,, Karlsen F,, Morland E,, Snijders PJ,, Meijer CJ. 2012. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol 50:23902396.
149. Chung HS,, Lee M. 9 February 2014. Comparison of the AdvanSure HPV GenoBlot assay with the INNO-LiPA HPV genotyping assay for human papillomavirus genotyping. J Clin Virol 10.1016/j.jcv.2014.01.027.
150. Kahng J,, Oh EJ,, Lee HN,, Lee DW,, Kim Y. 2014. Clinical validation of AdvanSure GenoBlot assay as primary screening and test of cure for human papillomavirus infection. Ann Lab Med 34:127133.
151. Chranioti A,, Spathis A,, Aga E,, Meristoudis C,, Pappas A,, Panayiotides I,, Karakitsos P. 2012. Comparison of two commercially available methods for HPV genotyping: CLART HPV2 and Linear Array HPV genotyping tests. Anal Quant Cytol Histol 34:257263.
152. Lin CY,, Chao A,, Yang YC,, Chou HH,, Ho CM,, Lin RW,, Chang TC,, Chiou JY,, Chao FY,, Wang KL,, Chien TY,, Hsueh S,, Huang CC,, Chen CJ,, Lai CH. 2008. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J Clin Virol 42:361367.
153. Liu SS,, Leung RC,, Chan KK,, Cheung AN,, Ngan HY. 2010. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J Clin Microbiol 48:758764.
154. Peng J,, Gao L,, Guo J,, Wang T,, Wang L,, Yao Q,, Zhu H,, Jin Q. 2103. Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes. J Clin Microbiol 51:402408.
155. Wong FK,, Ching JC,, Chow JK. 2010. Comparison of the DiagCor GenoFlow human papillomavirus array test and Roche Linear Array HPV genotyping test. Open Virol J 4:169174.
156. Wong OG,, Lo CK,, Chow JN,, Tsun OK,, Szeto E,, Liu SS,, Ngan HY,, Cheung AN. 2012. Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population. J Clin Microbiol 50:16911697.
157. Herraez-Hernandez E,, Alvarez-Perez M,, Navarro-Bustos G,, Esquivias J,, Alonso S,, Aneiros-Fernandez J,, Lacruz-Pelea C,, Sanchez-Aguera M,, Santamaria JS,, de Antonio JC,, Rodriguez-Peralto JL. 2013. HPV Direct Flow CHIP: a new human papillomavirus genotyping method based on direct PCR from crude-cell extracts. J Virol Methods 193:917.
158. Tao P,, Zheng W,, Wang Y,, Bian ML. 2009. Sensitive HPV genotyping based on the flow-through hybridization and gene chip. J Mol Diagn 11:439445.
159. Erali M,, Pattison DC,, Wittwer CT,, Petti CA. 2009. Human papillomavirus genotyping using an automated film-based chip array. J Mol Diagn 11:439445.
160. Else EA,, Swoyer R,, Zhang Y,, Taddeo FJ,, Bryan JT,, Lawson J,, Van Hyfte I,, Roberts CC. 2011. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol 49:19071912.
161. Tan SE,, Garland SM,, Rumbold AR,, Tabrizi SN. 2010. Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays. J Clin Microbiol 48:14581460.
162. Castle PE,, Gravitt PE,, Solomon D,, Wheeler CM,, Schiffman M. 2008. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 46:109117.
163. Bryant D,, Rai N,, Rowlands G,, Hibbitts S,, Jones J,, Tristram A,, Fiander A,, Powell N. 2011. Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA microarray. J Med Virol 83:13581361.
164. Didelot MN,, Boulle N,, Damay A,, Costes V,, Segondy M. 2011. Comparison of the PapilloCheck assay with the Digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes. J Med Virol 83:13771382.
165. Hesselink AT,, Heideman DA,, Berkhof J,, Topal F,, Pol RP,, Meijer CJ,, Snijders PJ. 2010. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 48:797801.
166. Tabrizi SN,, Stevens MP,, Khan ZA,, Chow C,, Devitt MA,, Garland SM. 2012. Comparison of PapType to Digene Hybrid Capture 2, Roche Linear Array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears. J Clin Microbiol 50:27962798.
167. Cuzick J,, Ho L,, Terry G,, Kleeman M,, Giddings M,, Austin J,, Cadman L,, Ashdown-Barr L,, Costa MJ,, Szarewski A. 14 February 2014. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol 60:4449.
168. Kim S,, Lee D,, Park S,, Kim TU,, Jeon BY,, Park KH,, Lee H. 2012. REBA HPV-ID for efficient genotyping of human papillomavirus in clinical samples from Korean patients. J Med Virol 84:12481253.
169. Lee YS,, Gong G,, Sohn JH,, Ryu KS,, Lee JH,, Khang SK,, Cho KJ,, Kim YM,, Kang CS. 2013. Cytological evaluation and REBA HPV-ID HPV testing of newly developed liquid-based cytology, EASYPREP: comparison with SurePath. Korean J Pathol 47:265274.


Generic image for table

Human alphapapillomavirus genotype diversity and clinical manifestations

Generic image for table

Clinical indications for appropriate use of HPV tests

Generic image for table

FDA-approved molecular assays for the detection and/or genotyping of high-risk HPV DNA

Generic image for table

hybridization tests for HPV detection

Generic image for table

Non-FDA-approved DNA/mRNA-based assays for the detection and limited genotyping of high-risk HPV DNA

Generic image for table

Non-FDA-approved DNA-based HPV detection and high-level genotyping assays


This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error